Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer

OBJECTIVES:

• Determine circulating levels of calgranulin A and calgranulin B in patients with estrogen receptor negative or estrogen receptor positive, newly diagnosed, primary stage I-III adenocarcinoma of the breast.

OUTLINE: This is a pilot study.

Patients undergo a blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B. Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

• Histologically confirmed primary adenocarcinoma of the breast

• Stage I-III disease
• No evidence of metastatic disease
• Newly diagnosed disease
• Hormone receptor status:

• Estrogen receptor-positive- or -negative tumor

PATIENT CHARACTERISTICS:

Sex

• Not specified

Menopausal status

• Not specified

Performance status

• Not specified

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• Not specified

Renal

• Not specified

Other

• Not pregnant
• No Crohn's disease
• No arthritis
• No psoriasis
• No lupus erythematosus
• No multiple sclerosis
• No other severe active inflammation
• Not C-reactive protein positive
• No HIV positivity
• No other serious medical or psychiatric illness

PRIOR CONCURRENT THERAPY:

Radiotherapy

• No prior radiotherapy for breast cancer

Surgery

• No prior organ transplantation

Other

• No prior systemic therapy for breast cancer